research use only

Caspofungin (MK-0991) Acetate Fungal inhibitor

Cat.No.S3073

Caspofungin Acetate (MK-0991, L-743872) is an lipopeptide antifungal β-1,3-glucan synthase inhibitor.
Jump to

Quality Control

Batch: Purity: 99.98%
99.98

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (82.41 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 50 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1213.42 Formula

C52H88N10O15.2C2H4O2

Storage (From the date of receipt) 3 years -20°C(in the dark) powder
CAS No. 179463-17-3 Download SDF Storage of Stock Solutions Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms L-743872 SMILES CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O

Read more about storage stability CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
β-1,3-glucan synthase
In vitro

Caspofungin acetate is the first in a new class of antifungals that inhibits the synthesis of beta (1, 3)-d-glucan, an essential component of the cell wall of filamentous fungi. Prior studies have shown in vitro activity of caspofungin acetate using the reference methods, broth microdilution or macrodilution, for antifungal susceptibility testing of Candida species established by the National Committee for Clinical Laboratory Standards 1997 guidelines against a variety of Candida species including Candida krusei. Although caspofungin acetate is only Food and Drug Administration-approved for the treatment of aspergillosis, there is information showing that many Candida species are susceptible. The minimal inhibitory concentration for 90% inhibition of Candida species by caspofungin acetate are as follows:C. albicans 0.5 μg/mL (range, 0.25-0.5), C. glabrata 1.0 μg/mL (range, 0.25-2.0), C. tropicalis 1.0 μg/mL (range, 0.25-1.0), C. parapsilosis 0.5 μg/mL (range, 0.25-1.0), and C. krusei 2.0 μg/mL (range, 0.5-2.0)

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/33917182/
  • [5] https://pubmed.ncbi.nlm.nih.gov/21518846/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-01)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07788586 NOT_YET_RECRUITING
Candidemia; Invasive Candidiasis
Oliver Cornely, MD
2026-09 PHASE4
NCT05421858 RECRUITING
Candidemia; Candidiasis, Invasive
Basilea Pharmaceutica
2024-12-11 PHASE3
NCT06194201 UNKNOWN
Patients With Candidemia and/or Invasive Candidiasis
Fujian Shengdi Pharmaceutical Co., Ltd.
2024-04-27 PHASE2
NCT06892951 NOT_YET_RECRUITING
Pneumocystis Pneumonia; Pneumocystis Jirovecii Infection; Pneumocystis Infections
University Hospital, Tours
2025-06 PHASE1; PHASE2
NCT04728971 UNKNOWN
Liver Transplantation
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2022-10-01 PHASE4
NCT03580733 UNKNOWN
ICU Yeast Intra-abdominal Infection
Centre Hospitalier Universitaire, Amiens
2019-01-01 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.